US Proposal Could Halve Biocon's Biosimilar Development Costs

Imagine there are very expensive medicines that help people with serious sicknesses like cancer.

These expensive medicines are called 'biological drugs.'

Doctors can now make 'biosimilars,' which are like copies of these expensive drugs but usually cost less.

To make these biosimilars, companies need to do lots of tests, which can be very costly and take a long time.

The United States is thinking about making the testing rules simpler, so companies don't have to do as many big tests.

Biocon, a company that makes these biosimilars, thinks this change will cut their testing costs in half!

This means they can make more biosimilars and bring them to people who need them faster and at a lower price.

Biocon wants to launch many new biosimilars in the next few years, especially in America and Europe, and this new rule could help them do just that.